Form 4: Vor Biopharma CEO Robert Ang Reports Stock Disposal to Cover Tax Obligations
SEC Form 4 Filing
Robert Ang, CEO of Vor Biopharma, disposed of 2,787 shares of common stock on February 6, 2025, to satisfy tax withholding obligations related to the settlement of restricted stock units.
Summary
- On February 6, 2025, Robert Ang, the President and CEO of Vor Biopharma Inc., disposed of 2,787 shares of common stock.
- The transaction was executed to cover tax withholding obligations associated with the settlement of restricted stock units.
- Following the transaction, Ang directly owns 918,952 shares of Vor Biopharma Inc.
- The shares were sold at a price of $1.5.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to stock transactions for tax purposes, indicating a neutral sentiment.
Industry Context
Form 4 filings are standard practice for company insiders to report transactions in their company's stock, providing transparency to investors.
Stakeholder Impact
- The transaction has a minimal impact on stakeholders as it is a routine sale of shares to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| 02/06/2025 | Date of stock disposal to cover tax obligations. |
| 02/07/2025 | Date of signature by Attorney-in-Fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.